Clinical Trial

A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

Name: A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF — clinical trial record (NCT07653100)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.

Protocol Amendment History 1 change

notable Trial sites expanded: 5 -> 10 locations 2026-07-10

Trial Details

NCT Number	NCT07653100
Lead Sponsor	Pfizer
Conditions	Respiratory Syncytial Virus (RSV)
Enrollment	540 participants
Start Date	2026-06-22
Primary Completion	2027-01-25 (estimated)
Study Completion	2027-01-25 (estimated)
Updated on ClinicalTrials.gov	2026-07-09